The economic burden of Lupus Nephritis: a systematic literature review
The economic burden of Lupus Nephritis: a systematic literature review
INTRODUCTION: Few studies have evaluated the economic burden of lupus nephritis (LN). The aim of this systematic literature review (SLR) was to assess the economic burden (direct and indirect costs, and healthcare resource utilization [HCRU]) associated with LN, with particular focus on the burden of renal flares and end-stage kidney disease (ESKD).
METHODS: This SLR (GSK study 213531) was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Searches of the MEDLINE and Embase databases were conducted for English language publications reporting cost or HCRU data in patients with LN (regardless of age or LN histological class) until December 10, 2019. Handsearching of conference proceedings and keyword-based searches in PubMed, Google, and Google Scholar were also conducted.
RESULTS: Twenty-two studies were identified from 28 publications reporting the cost (n = 19) and HCRU (n = 13) associated with LN. Most studies were from North America (n = 13) and many used administrative claims data (n = 9). LN was associated with substantially higher direct costs (e.g., total annual, hospitalization, and ESKD-related direct costs), total indirect costs, and HCRU (e.g., hospitalization, outpatient services, and medication use) compared with patients without systemic lupus erythematosus (SLE) or non-renal SLE controls. ESKD and dialysis were significant contributors to economic burden. No studies described the cost of renal flares.
CONCLUSIONS: The consensus across the 22 studies was that the economic burden of LN is substantial, particularly in active or severe disease, or if there is progression to ESKD. Total direct cost may be underestimated in claims data given the challenges of identifying patients with LN. Further studies are vital to ascertain the cost of renal flares; a renal flare is likely to result in a period of increased HCRU, which could be mitigated by treatments that extend renal remission.
Cost, Economic burden, Lupus nephritis, Systematic literature review, Systemic lupus erythematosus
25-47
Thompson, Juliette C
28a24d4b-8b21-436c-85db-0b6608c46a09
Mahajan, Anadi
cb32dc9e-026e-42b3-9f3a-9a1459914c9e
Scott, David A
19b5fd34-9974-4ae4-8be0-27a693639e20
Gairy, Kerry
c6b69587-bb83-4169-9343-59e7dfeb8ebe
1 February 2022
Thompson, Juliette C
28a24d4b-8b21-436c-85db-0b6608c46a09
Mahajan, Anadi
cb32dc9e-026e-42b3-9f3a-9a1459914c9e
Scott, David A
19b5fd34-9974-4ae4-8be0-27a693639e20
Gairy, Kerry
c6b69587-bb83-4169-9343-59e7dfeb8ebe
Thompson, Juliette C, Mahajan, Anadi, Scott, David A and Gairy, Kerry
(2022)
The economic burden of Lupus Nephritis: a systematic literature review.
Rheumatology and therapy, 9 (1), .
(doi:10.1007/s40744-021-00368-y).
Abstract
INTRODUCTION: Few studies have evaluated the economic burden of lupus nephritis (LN). The aim of this systematic literature review (SLR) was to assess the economic burden (direct and indirect costs, and healthcare resource utilization [HCRU]) associated with LN, with particular focus on the burden of renal flares and end-stage kidney disease (ESKD).
METHODS: This SLR (GSK study 213531) was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Searches of the MEDLINE and Embase databases were conducted for English language publications reporting cost or HCRU data in patients with LN (regardless of age or LN histological class) until December 10, 2019. Handsearching of conference proceedings and keyword-based searches in PubMed, Google, and Google Scholar were also conducted.
RESULTS: Twenty-two studies were identified from 28 publications reporting the cost (n = 19) and HCRU (n = 13) associated with LN. Most studies were from North America (n = 13) and many used administrative claims data (n = 9). LN was associated with substantially higher direct costs (e.g., total annual, hospitalization, and ESKD-related direct costs), total indirect costs, and HCRU (e.g., hospitalization, outpatient services, and medication use) compared with patients without systemic lupus erythematosus (SLE) or non-renal SLE controls. ESKD and dialysis were significant contributors to economic burden. No studies described the cost of renal flares.
CONCLUSIONS: The consensus across the 22 studies was that the economic burden of LN is substantial, particularly in active or severe disease, or if there is progression to ESKD. Total direct cost may be underestimated in claims data given the challenges of identifying patients with LN. Further studies are vital to ascertain the cost of renal flares; a renal flare is likely to result in a period of increased HCRU, which could be mitigated by treatments that extend renal remission.
Text
Thompson2022_Article_TheEconomicBurdenOfLupusNephri
- Version of Record
More information
Accepted/In Press date: 27 August 2021
e-pub ahead of print date: 3 November 2021
Published date: 1 February 2022
Keywords:
Cost, Economic burden, Lupus nephritis, Systematic literature review, Systemic lupus erythematosus
Identifiers
Local EPrints ID: 454924
URI: http://eprints.soton.ac.uk/id/eprint/454924
ISSN: 2198-6576
PURE UUID: 15c8982c-9110-4db6-b51e-a46d9eaf8ce9
Catalogue record
Date deposited: 01 Mar 2022 17:48
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
Juliette C Thompson
Author:
Anadi Mahajan
Author:
David A Scott
Author:
Kerry Gairy
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics